Marinomed Biotech AG announces positive data demonstrating Carragelose efficacy against SARS-CoV-2 variants
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi8dX1whjAO8D5uX03NAM_zoyJd7lwAgmf3gROsF00KR3HQZI8rajASh4ROGahRRPTwvu41pOBfgrpmGj2K90AaVnjvY6ii97A0ATlwPs4VSwXFU9Uhb4AWnz6YCcFdGcd0OLQNaBX5k0Q/w480-h640/betadine+carragelose.jpg)
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Carragelose inactivates the new, rapidly spreading variants and SARS-CoV-2 wildtype with similar efficacy in vitro . The Company tested the three variants that currently mostly drive the COVID-19 pandemic, namely the so-called British or B.1.1.7, the South-African or B.1.351, and the Brazilian or P1 variant.[*] The data demonstrate that also with increasing prevalence of virus variants, the marketed OTC Carragelose-based lozenges, nasal and throat sprays will continue to effectively contribute to combatting the COVID-19 pandemic. “The COVID-19 pandemic continues to be a major health, social, and economic burden, and we now see variants of SARS-CoV-2 taking over the dynamics of the pandemic. We are very confident in these results that show Carragelose inactivates SARS-CoV-2, independent of the mutat